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Weperformeda retrospectiveanalysis on the outcomesof 135hematopoietic stemcell transplantations (HSCTs)
for primary immunodeﬁciency disorders in Australian and New Zealand Children’s Haematology Oncology
Group transplantation centers between 1992 and 2008. The most common indications for HSCT were severe
combined immunodeﬁciency,Wiskott-Aldrich syndrome, and chronic granulomatous disease. Five-year overall
survival (OS) was 72% for the entire cohort. Disease-speciﬁc 5-year OS was 70% for severe combined immu-
nodeﬁciency, 81% forWiskott-Aldrich syndrome, and 69% for chronic granulomatous disease. Transplantation-
relatedmortality (TRM)was 10% at dayþ100. TRMandOSwere equivalent in recipients of related and unrelated
donor transplants. Source of stem cells had no impact on TRM or OS with outcomes following unrelated
umbilical cord blood similar to unrelated bone marrow. The presence of interstitial pneumonitis, active cyto-
megalovirus infection, or veno-occlusive diseasewere all independent variables that signiﬁcantly decreasedOS.
This largeseries supports theuseofHSCTas curative therapy for a rangeof primary immunodeﬁciencydisorders,
demonstrating excellent survival after both related and unrelated donor transplantation.
Crown Copyright  2013 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow
Transplantation. All rights reserved.INTRODUCTION selected subsets in this group [9,10]. The beneﬁt of reduced
Hematopoietic stem cell transplantation (HSCT) has been
the standard of treatment for primary immunodeﬁciency
disorders (PIDs) in the pediatric population for decades. The
ﬁrst successful pediatric bone marrow transplantation was
performed in 1968 on a child with severe combined immu-
nodeﬁciency (SCID) using a histocompatible sibling donor
[1]. HSCT has proven to be an effective treatment for a range
of PIDs [2-6]. The initial success with matched sibling donors
has been expanded to include the use of both unrelated
marrow and umbilical cord blood grafts [7,8]. The use of cord
blood in HSCT is increasing, and the advantages of rapid
availability, decreased risk of viral transmission, and
decreased rates of GVHD make cord blood an appealing
source of donor stem cells for this population.
The use of reduced-intensity conditioning (RIC) regimens
has been explored, and some support the use of RIC inedgments on page 343.
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12.11.619late effects with RIC is balanced by the challenge of achieving
durable long-term engraftment.
Advancements in donor selection, pretransplantation
conditioning, and supportive care have contributed to
excellent outcomes in recent years. A 5-year overall survival
(OS) of 84% has been reported in patients with Wiskott-
Aldrich syndrome (WAS) [11]. Outcomes for patients
with SCID appear to be dependent on subtype. Gennery et al.
[12] reported a 10-year survival of 70% for B(þ) SCID, as
opposed to only 51% for the B() subtype. A recent multi-
center study of ADA-SCID outcomes reported a 5-year OS of
67% [13].
In this retrospective review, we analyzed the outcomes of
135 HSCTs performed in patients with PIDs at 6 Australian
and New Zealand Children’s Haematology Oncology Group
pediatric transplantation centers between 1992 and 2008
using both related and unrelated donors (including unre-
lated marrow and cord blood). We examined transplantation
outcomes (engraftment, graft-versus-host disease [GVHD],
transplantation-related mortality [TRM], and OS) and tested
variables for signiﬁcant effects on these outcomes.c. on behalf of American Society for Blood and Marrow
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All patients were selected from the Australasian Bone Marrow Trans-
plant Recipient Registry (ABMTRR), which has recordedmore than 95% of all
HSCT activity in Australia since 1992 and in New Zealand since 1998 [14].
Patient consent for data reporting to ABMTRR was obtained by individual
participating institutions. Patient consent for HSCT was obtained by indi-
vidual institutions based on local Ethics Board requirements.
Recipients and donors were initially matched at HLA-A and -B loci by
serologic methods and at -DR loci by molecular techniques. Since 2000,
high-resolution allele typing at a minimum of 8 loci (HLA-A, -B, -C, -DRB1)
has been performed in the majority of donorerecipient marrow pairs. Cord
blood recipients were matched serologically or, more recently, by low/
intermediate molecular resolution for -A and -B and at high molecular
resolution for -DRB1.
All patients were cared for in single rooms ventilated with a high-
efﬁciency particulate air ﬁltration system. Patients at high risk for cyto-
megalovirus (CMV) infection received prophylactic ganciclovir up to
day þ100 once neutrophil engraftment had occurred or as preemptive
therapy together with surveillance testing using CMV antigenemia or CMV
PCR screening. Patients with a history of herpes simplex infection received
prophylactic i.v. acyclovir. After engraftment, all patients received Pneumo-
cystis carinii prophylaxis with co-trimoxazole or an appropriate alternative
in cases of allergy. Episodes of fever were treated with broad-spectrum
empiric antibiotics and antifungal therapy in accordance with individual
institutional protocols.
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days of
an absolute neutrophil count of 0.5  109/L. Platelet engraftment wasTable 1
Patient Characteristics
Characteristic n (%)
Total patients 135
Recipient sex
Male 107 (79)
Female 28 (21)
Year of HSCT
1992-1999 53 (39)
2000-2008 82 (61)
Indication for transplant
Chediak-Higashi syndrome 2 (1)
CGD 16 (12)
Congenital neutropenia/Kostmann syndrome 7 (5)
Di George syndrome 2 (1)
Leukocyte adhesion disorder 3 (3)
Omenn syndrome 6 (5)
SCID 65 (48)
WAS 27 (20)
X-linked hyper-IgM syndrome 2 (1)
X-linked lymphoproliferative syndrome 5 (4)
Conditioning regimen
Bu þ Cy with or without antithymocyte globulin 44 (32)
Bu þ Cy þ other 21 (15)
Fludarabine þ other (RIC) 34 (25)
Cy þ other 13 (10)
None 23 (17)
Unknown 1 (1)
Donor relation
HLA-identical sibling 28 (21)
HLA-mismatched sibling 6 (5)
HLA-identical other related 10 (7)
HLA-mismatched other related 31 (23)
HLA-identical unrelated 42 (31)
HLA-mismatched unrelated 18 (13)
Cell source
Bone marrow 92 (68)
Peripheral blood 9 (7)
Cord blood 33 (24)
Bone marrow and cord blood 1 (1)
GVHD prophylaxis
T cell depletion 20 (15)
Cyclosporin only 27 (20)
Cyclosporin þ methotrexate 42 (31)
Cyclosporin þ mycophenolate 15 (11)
Cyclosporin þ other 19 (14)
Other 4 (3)
None 6 (5)
Unknown 2 (1)deﬁned as a platelet count of 20  109/L measured a minimum of 7 days
after the last platelet transfusion. Assessment and grading of acute GVHD
(aGVHD) and chronic GVHD (cGVHD) were done using established stan-
dardized criteria [15,16]. TRM was deﬁned as death from any cause other
than persistent disease.
Various conditioning regimens were used, reﬂecting the differing
underlyingdiagnoses, donor sources, transplantation centerpreferences, and
era of transplantation (Table 1). The majority of patients received a myeloa-
blative regimen (58%), and 25% received RIC regimen. Twenty-three patients
with SCID (17%) received no conditioning. The most common myeloablative
regimen used was busulfan (Bu) 16 mg/kg and cyclophosphamide (Cy) 200
mg/kg (32%). Melphalan, etoposide, or ﬂudarabine was added to Bu/Cy in 21
patients (15%). A further 10% of patients received a myeloablative regimen
using Cy with cytarabine, thiotepa, or melphalan, with 3 patients also
receiving total body irradation or total lymphocyte irradiation.Myeloablative
conditioning included in vivo T cell depletion using either antithymocyte
globulin or alemtuzumab in 33 patients (43%). All RIC regimens (34 patients;
25%) included ﬂudarabine, with antithymocyte globulin or alemtuzumab
added in 26 (76%) of these patients. Fludarabine was used alone or in
combinationwith reduced-dose Bu, Cy, melphalan, or treosulphan. Ex vivo T
cell depletion was performed in 29% of HSCTs, using either RBC rosette or
positive CD34þ cell selection, depending on the year of transplantation.
GVHD prophylaxis varied depending on stem cell source and institution.
A combination of cyclosporin and methotrexate was the most common
regimen used and was standard for all matched sibling/family donor and T
cellereplete unrelated donor transplants. Recipients of an ex vivo
T celledepleted donor graft received cyclosporin alone. Some cord blood
recipients received cyclosporin and methotrexate in combination with
steroids before 2000, after which time cyclosporin and steroids or cyclo-
sporin and mycophenolate combinations were used. A minority of patients
received tacrolimus as an alternative to cyclosporin, as a single agent or in
combination with mycophenolate.
The close-out date for this study was June 30, 2011, and survival
statistics are based on that date. OS curves were produced using the method
of Kaplan and Meier, and the Cox proportional hazards model was used to
perform univariate and multivariate analysis of risk factors and their inﬂu-
ence on outcomes. The following variables were tested for their association
with time to neutrophil engraftment, incidence of aGVHD, TRM, and OS: sex,
age, year of HSCT, time from diagnosis to HSCT, donorerecipient relation-
ship, donorerecipient HLA compatibility, stem cell source, donor and
recipient CMV seropositivity, pretransplantation conditioning, GVHD and
CMV prophylaxis, and incidence of adverse events immediately post-
transplantation, which were entered as time-dependent variables. Statis-
tical analyses were performed using SPSS version 19 (IBM, Armonk, NY).
RESULTS
A total of 135 children underwent initial HSCT for a PID.
Table 1 summarizes patient characteristics. Indications for
HSCT included a diagnosis of SCID, WAS, chronic granulo-
matous disease (CGD), congenital neutropenia/Kostmann
syndrome, Omenn syndrome, X-linked lymphoproliferative
syndrome, leukocyte adhesion deﬁciency, X-linked hyper-
IgM syndrome, Di George syndrome, or Chediak-Higashi
syndrome. The median age at transplantation was 1 year
(range, 0-15 years), and the cohort was 79% male. The
median age of donors was 13 years (range, 0-51 years). Of the
donors, 28% were HLA-matched related (21% matched
sibling, 7% other matched related), 28% were mismatched
related, and 44% were unrelated. Cord blood was used in 54%
of unrelated donor transplantations. The median cry-
opreserved cord blood cell dose was 8.0  107/kg (range, 1.3-
138.0  107/kg) for total nucleated cells and 3.1  105/kg
(range, 0.9-57.0  105/kg) for CD34þ cells.
The median time from diagnosis to HSCT for the entire
cohort was 6 months (range, 0-163 months). A greater
number of transplantations were performed in the more
recent time period, with 82 in 2000-2008 compared with 53
in 1992-1999. The median patient follow-up for the entire
cohort was 6.03 years (range, 0.39-17.31 years).
Engraftment
The median time to neutrophil and platelet engraftment
was 16 days (range, 1-62 days) and 30 days (range, 1-112
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Figure 2. TRM in recipients of unrelated bone marrow and cord blood
transplants.
Table 2
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dence (CI) at day þ42 of 86% and 63%, respectively. The rate
of overall neutrophil engraftment was 89%, and that of
platelet engraftment was 85%. Univariate analysis demon-
strated an association between the use of an HLA-identical
sibling donor and a decreased time to neutrophil engraft-
ment (P¼ .03). This result was not signiﬁcant on multivariate
analysis, however. Variables that showed no signiﬁcant
impact on engraftment in our cohort included age at trans-
plantation, time from diagnosis to transplantation, and
donor source.
Eighteen patients required a second HSCT owing to graft
failure or rejection. Nine of these patients had received an
HLA-identical unrelated donor marrow or cord blood graft in
their initial HSCT, 2 had received a matched sibling trans-
plant, and 7 had received a mismatched parental donor
transplant. For the second HSCT, 9 patients received an HLA-
identical unrelated donor transplant, 4 received a hap-
loidentical parent transplant, 2 received a matched sibling
transplant, 2 received a mismatched related donor trans-
plant, and 1 received a mismatched unrelated donor trans-
plant. Nine of these patients are alive, 5 died from
posttransplantation infection, 2 died from acute respiratory
distress syndrome, and 1 died from graft failure. Four
patients underwent a third HSCT: 3 with HLA-identical
unrelated bone marrow and 1 with a matched related
transplant. Of those 4 patients, 3 were alive at the time of this
report, and 1 died from interstitial pneumonitis.
GVHD
The day þ100 CI for aGVHD was 25% for grade II-IV
aGVHD and 10% for grade III-IV aGVHD. The 1-year CI for
cGVHD was 16%, but only 7% for extensive cGVHD. The use of
a fully matched sibling donor was associated with
a decreased risk of aGVHD on both univariate analysis (P ¼
.01) and multivariate analysis (P ¼ .002). HSCT performed
after 1998 also was associated with a decreased risk of
aGVHD on both univariate analysis (P ¼ .005) and multivar-
iate analysis (P ¼ .002). Variables with no signiﬁcant impact
on the incidence of aGVHD were age at transplantation, time
from diagnosis to transplantation, donor cell source, HLA
match, and ex vivo T cell depletion.
TRM
The CI of TRM was 10% at day þ100 and 22% at 1 year.
Analysis of TRM at 1 year showed no differences among
recipients of matched sibling donor grafts (17.7%), unrelated
donor grafts (16.9%), unrelated cord blood (16%), and unre-
lated marrow (19%) (Figures 1 and 2). Variables associated
with a signiﬁcantly increased risk of TRM on univariate0%
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Figure 1. TRM in recipients of sibling and unrelated donor transplants.analysis were ex vivo T cell depletion (P ¼ .02), grade II-IV
aGVHD (P ¼ .01), grade III-IV aGVHD (P ¼ .02), hemorrhagic
cystitis (P ¼ .02), active CMV infection (P ¼ .001), interstitial
pneumonitis (P < .001), and veno-occlusive disease (P ¼ .02)
(Table 2). In the multivariate analysis, active CMV disease
(P ¼ .003), interstitial pneumonitis (P ¼ .001), and veno-
occlusive disease (P ¼ .006) remained signiﬁcant (Table 3).
Variables with no signiﬁcant affect on TRM were age at
transplantation, HLA match, donor cell source, time from
diagnosis to transplantation, CMV serostatus of donor or
recipient, HSCT after 1998, and type of conditioning regimen.OS
The 5-year OS for the cohort at was 72%; a breakdown of
survival by diagnosis is shown in Figure 3. The 5-year OS for
both matched sibling donor transplant and unrelated donor
transplant recipients was 79% (unrelated cord blood, 84%;
unrelated marrow, 73%). There was no signiﬁcant difference
in OS between matched sibling donor graft and unrelated
donor graft recipients (P ¼ .90) (Figure 4), and among unre-
lated donors there was no signiﬁcant difference in OS
between cord blood recipients and bone marrow recipients
(P ¼ .40) (Figure 5).
A total of 36 deaths were reported, 3 of which occurred 2
or more years after HSCT (Table 4). Primary causes of death
included infection, interstitial pneumonitis (noninfectious),
GVHD, graft failure, organ failure, hemorrhage, and acute
respiratory distress syndrome (noninfectious). Two patients
developed a secondary malignancy posttransplantation: 1
with an embryonal liver sarcoma (primary diagnosis, SCID)
and 1 with Epstein-Barr viruserelated lymphoproliferative
disease (primary diagnosis, congenital neutropenia). Rates ofUnivariate Analysis of TRM
Hazard Ratio P Value
Age >1 year at HSCT 0.68 .30
Less than 3 months from diagnosis to HSCT 1.17 .70
HLA 6/6 match 0.78 .50
Donor source: cord blood 0.53 .20
Donor source: bone marrow or peripheral
blood
1.55 .30
Reduced-intensity conditioning 1.21 .60
Ex vivo T cell depletion 2.20 .02
Grade II-IV aGVHD 2.38 .01
Grade III-IV aGVHD 2.66 .02
Hemorrhagic cystitis 3.66 .02
CMV infection 3.40 .001
Interstitial pneumonitis 6.66 <.001
Veno-occlusive disease 2.61 .02
Table 3
Multivariate Analysis of TRM
Hazard Ratio 95% Conﬁdence
Interval
P Value
CMV infection 3.30 1.52-7.16 .003
Interstitial pneumonitis 3.47 1.63-7.40 .001
Veno-occlusive disease 3.65 1.46-9.09 .006
Immunodeficiencies: 5-year overall
survival by donor type
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Figure 4. Five-year OS in recipients of sibling and unrelated donor transplants.
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disease, 15% for interstitial pneumonitis, 13% for veno-
occlusive disease, and 4% for hemorrhagic cystitis 4%
(Table 5).
Factors associated with a negative impact on OS on
univariate analysis were ex vivo T cell depletion (P ¼ .01),
grade II-IV aGVHD (P ¼ .03), grade III-IV aGVHD (P ¼ .04),
hemorrhagic cystitis (P ¼ .02), active CMV disease (P ¼ .002),
interstitial pneumonitis (P < .001), and veno-occlusive
disease (P ¼ .03) (Table 6). When entered into our multi-
variate model, only active CMV disease (P ¼ .01), interstitial
pneumonitis (P¼ .001), and veno-occlusive disease (P¼ .005)
retained a signiﬁcant association (Table 7).
We also examined the effect of type of conditioning
regimen, comparing RIC and myeloablative regimens, and
found no signiﬁcant difference in OS (P ¼ .40). Other factors
with no signiﬁcant impact on OS included age at trans-
plantation, donor cell source, time from diagnosis to trans-
plantation, and HSCT after 1998.
Disease-Speciﬁc Results
SCID
In the 65 patients with SCID, the median time from
diagnosis to transplantation was 2 months (range, 0-163
months), and the median time to neutrophil engraftment
posttransplantationwas 14 days, with a CI at dayþ42 of 82%.
Rates of aGVHD at day þ100 were 25% for grade II-IV aGVHD
and 9% for grade III-IV aGVHD. The CI of cGVHD was 11% at 1
year (5% for extensive cGVHD). The TRM was 9% at day þ100
and 23% at 1 year posttransplantation. The 5-year OS was
70% for the SCID cohort.
WAS
The 27 patients with WAS had a median time from
diagnosis to transplantation of 10 months (range, 2-161
months) and a median time to neutrophil engraftment of 150 1 2 3 4 5
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Figure 3. Five-year OS for the entire cohort was 72%, including 81% in patients
with WAS, 70% in patients with SCID, 69% in patients with CGD, and 71% in
patients with other immunodeﬁciencies.days, with a dayþ42 CI of 92%. At dayþ100, the rate of grade
II-IV aGVHD was 31%, and that of grade III-IV was 12%. The CI
of cGVHD was 25% at 1 year (8% for extensive cGVHD). TRM
was 11% at day þ100 and 19% at 1 year. The WAS cohort had
a 5-year OS of 81%.
CGD
In the 16 patients with CGD, the median time from
diagnosis to transplantation was 29 months (range, 0-141
months), and the median time to neutrophil engraftment
was 17 days, with a dayþ42 CI of 100%. The rate of grade II-IV
aGVHD at day þ100 was 38%, and that of grade III-IV aGVHD
was 25%. The CI of chronic GVHD at 1 year was 26% (19% for
extensive cGVHD). TRM was 6% at day þ100 and 25% at 1
year. The 5-year OS was 69% for the CGD cohort.DISCUSSION
Patients with PIDs were the ﬁrst pediatric cohort treated
with HSCT. Signiﬁcant advances in HSCT over the ensuing
years, including improved HLA selection, better-tailored
conditioning regimens, improved GVHD prophylaxis, and
the use of alternative stem cell sources, have helped improve
outcomes in this population. In the present study, we report
excellent survival in a large cohort of patients with PIDs, withImmunodeficiencies: 5-year overall
survival by donor type and cell source
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Figure 5. Five-year OS in recipients of unrelated bone marrow and cord blood
transplants.
Table 4
Primary Causes of Death
Cause of Death n (%)
Infection 8 (22)
Interstitial pneumonitis 6 (17)
Graft failure 5 (14)
GVHD 5 (14)
Organ failure 5 (14)
Hemorrhage 4 (11)
Acute respiratory distress syndrome 3 (8)
Total 36 (100)
Table 6
Univariate Analysis of OS
Hazard
Ratio
P Value
Age >1 year at HSCT 0.65 .20
More than 3 months from diagnosis to HSCT 1.14 .70
HSCT after 1998 0.99 .90
Stem cell source: cord blood 0.48 .10
Stem cell source: bone marrow or peripheral blood 1.71 .20
Ex vivo T cell depletion 2.37 .01
Grade II-IV aGVHD 2.07 .03
Grade III-IV aGVHD 2.40 .04
Hemorrhagic cystitis 3.36 .02
CMV infection 2.98 .002
Interstitial pneumonitis 5.80 <.001
Veno-occlusive disease 2.35 .03
R. Mitchell et al. / Biol Blood Marrow Transplant 19 (2013) 338e343342low rates of TRM. These results are in agreement with
recently published international data [9,11]. In 88 patients
with PID who underwent unrelated cord blood HSCT, Morio
et al. [9] reported a 5-year OS of 69% (71% for patients with
SCID and 82% for those with WAS). Our data are comparable,
with a 5-year OS of 72% for the entire cohort, 70% for the SCID
group, and 81% for the WAS group.
The use of unrelated donors in HSCT for PID continues to
increase, with published survival outcomes approaching
those for matched sibling donor HSCT [17,18]. The present
study included both related and unrelated donor trans-
plantation. There were no signiﬁcant differences in TRM or
OS between matched sibling donor graft recipients and
unrelated donor graft recipients. These ﬁndings support the
use of unrelated donors in cases when a matched sibling
donor is not available. In addition, there was also no signif-
icant difference in TRM or OS between unrelated bone
marrow recipients and cord blood recipients. This ﬁnding
supports the increased use of cord blood for HSCT in this
population, with its associated advantages of rapid accessi-
bility and decreased rates of aGVHD [8].
The role of ex vivo T cell depletion in decreasing rates of
aGVHD after HSCT for nonmalignant conditions has been
explored. We found that ex vivo T cell depletion had no
signiﬁcant inﬂuence on the rate of aGVHD. This unexpected
result may be related to the small number of patients who
received ex vivo T celledepleted grafts. Our ﬁndings do show
that ex vivo T cell depletion independently increased the risk
of TRM on univariate analysis, but this association did not
remain signiﬁcant on multivariate analysis. In this retro-
spective study on registry data, we were not able to assess
the impact of in vivo T cell depletion on mortality and
morbidity, particularly infection and immune reconstitution,
as an independent variable.
The role of RIC in the PID population remains to be
determined and may be an attractive option for a group of
patients who often have signiﬁcant comorbidities and pre-
existing infectious conditions. There is literature supporting
the use of RIC in matched sibling and unrelated marrow
donor transplantations for particular subsets of the PID
population [10], and recently published data demonstrate
the successful use of RIC in cord blood HSCT for both SCID [9]
and other PIDs [19]. Furthermore, there is a growing appre-
ciation that stable mixed chimerism in some, but not all, PIDTable 5
Adverse Events Posttransplantation
Adverse Event n (%)
CMV disease 26 (19)
Interstitial pneumonitis 20 (15)
Veno-occlusive disease 18 (13)
Hemorrhagic cystitis 6 (4)
Total 70subclasses is compatible with satisfactory longer-term blood
and immune function [19,20]. Our ﬁndings demonstrate no
signiﬁcant difference in survival between patients who
received myeloablative conditioning and those who received
RIC, but this comparison is limited by our small number of
patients.
Infection in the peritransplantation and post-
transplantation periods remains one of the most serious risk
factors affecting survival in the PID population [9,21].
Whereas CMV detection has improvedwith advancements in
PCR technology, enabling preemptive treatment of reac-
tivation, our data indicate that patients who develop active
CMV disease continue to be at elevated risk of increased
mortality and decreased survival. This ﬁnding suggests that
other therapies are needed to help treat active CMV infection.
Improvements in supportive care are thought to have
contributed to improved outcomes in patients with PID, with
studies reporting differences in survival in comparable
groups of patients depending on the era in which they
underwent HSCT [11,22]. In the present study, undergoing
HSCT after 1998 was associated with a decreased risk of
aGVHD, but had no signiﬁcant impact on TRM or OS. This
unexpected result warrants further investigation into the
changes in supportive care and the use of higher-resolution
typing and their effects on HSCT outcomes. One limitation
of a registry-based study is the lack of detailed information
on pretransplantation infection and comorbidity, which
could be a confounding variable on outcome. We used time
to transplantation as a surrogate for comorbidity, and found
no signiﬁcant impact on TRM or survival.
The main limitation of this study is the nature of retro-
spective analysis of registry data. The reliance on individual
institutions to interpret and report results increases vari-
ability, and future studies would beneﬁt from more detail in
terms of disease subtype and doses of chemotherapy agents.
Long-term follow-up of this patient cohort is of value, given
that this population did not survive before the era of HSCT.
The Center for International Blood and Marrow Trans-
plantation Research recently reported higher late mortality
rates for patients with PID and inborn errors of metabolism
compared with the general population, with cGVHD andTable 7
Multivariate Analysis of OS
Hazard Ratio 95% Conﬁdence
Interval
P Value
CMV infection 2.74 1.26-5.99 .01
Interstitial pneumonitis 3.76 1.17-8.24 .001
Veno-occlusive disease 3.82 1.52-9.65 .005
R. Mitchell et al. / Biol Blood Marrow Transplant 19 (2013) 338e343 343organ failure themain causes of death [23]. Haddad et al. [24]
reported that cGVHD and infection had a strong impact on
survival at more than 6 months posttransplantation in
patients with SCID. The possible role of RIC in preventing
organ toxicity, reducing rates of secondary malignancy, and
improving long-term survival remains unclear.
In this population of patients with rare disorders,
a cooperative approach is the best way to advance the
collective knowledge of HSCT. Owing to the retrospective
nature of this registry study, we are not able to report
information on disease molecular subtypes, donor chime-
rism, or immune reconstitution outcomes. Future studies
should look to incorporate multicenter results, with data
collected in a prospective fashion, to allow for better analysis
of HSCT outcomes.
The future direction of treatment of patients with PIDs
likely will involve incorporation of gene technology into
transplantation techniques. There have been reports of
successful correction of PIDs after autologous marrow har-
vesting, ex vivo gene transfer into hematopoietic cells, and
subsequent reinfusion of corrected CD34þ cells. Unfortu-
nately, insertional mutagenesis associated with the use of
retroviral vectors led to the development of leukemia in
some of these treated children, interrupting progress in the
ﬁeld while safer means of achieving gene transfer were
investigated. The more recent work with self-inactivating
lentiviral vectors appears to decrease the risk of insertional
mutagenesis and is likely to contribute to improved
outcomes in this population [25,26]. For the majority of
children with PIDs, allogeneic HSCT remains the therapy of
choice, with both related and unrelated donor stem cell
grafts offering a high likelihood of survival with correction of
the genetic disorder.
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